LY2624803 - Capsules + Zolpidem - Tablets + Placebo - Capsules + Placebo - Tablets
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Transient Insomnia
Conditions
Transient Insomnia
Trial Timeline
May 1, 2008 → Nov 1, 2008
NCT ID
NCT01779830About LY2624803 - Capsules + Zolpidem - Tablets + Placebo - Capsules + Placebo - Tablets
LY2624803 - Capsules + Zolpidem - Tablets + Placebo - Capsules + Placebo - Tablets is a phase 1 stage product being developed by Eli Lilly for Transient Insomnia. The current trial status is completed. This product is registered under clinical trial identifier NCT01779830. Target conditions include Transient Insomnia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01779830 | Phase 1 | Completed |
Competing Products
10 competing products in Transient Insomnia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Gabapentin + Gabapentin + Placebo | Pfizer | Phase 3 | 76 |
| Gabapentin + Gabapentin + Placebo | Pfizer | Phase 3 | 76 |
| Gabapentin + Gabapentin + Placebo | Pfizer | Phase 3 | 76 |
| Gabapentin + Placebo | Pfizer | Phase 3 | 76 |
| Gabapentin + Gabapentin + Placebo | Pfizer | Phase 3 | 76 |
| Gabapentin | Pfizer | Phase 3 | 76 |
| Gabapentin + Placebo | Pfizer | Phase 3 | 76 |
| Milvexian + Placebo | Bristol Myers Squibb | Phase 3 | 76 |
| Apixaban + Warfarin | Bristol Myers Squibb | Phase 3 | 76 |
| Levosimendan + Placebo | Orion Corporation | Phase 2 | 49 |